These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 31209181

  • 1. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
    Chan WK, Horvath TD, Tan L, Link T, Harutyunyan KG, Pontikos MA, Anishkin A, Du D, Martin LA, Yin E, Rempe SB, Sukharev S, Konopleva M, Weinstein JN, Lorenzi PL.
    Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
    [Abstract] [Full Text] [Related]

  • 2. Tumoral microenvironment prevents de novo asparagine biosynthesis in B cell lymphoma, regardless of ASNS expression.
    Grima-Reyes M, Vandenberghe A, Nemazanyy I, Meola P, Paul R, Reverso-Meinietti J, Martinez-Turtos A, Nottet N, Chan WK, Lorenzi PL, Marchetti S, Ricci JE, Chiche J.
    Sci Adv; 2022 Jul 08; 8(27):eabn6491. PubMed ID: 35857457
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.
    Panosyan EH, Wang Y, Xia P, Lee WN, Pak Y, Laks DR, Lin HJ, Moore TB, Cloughesy TF, Kornblum HI, Lasky JL.
    Mol Cancer Res; 2014 May 08; 12(5):694-702. PubMed ID: 24505127
    [Abstract] [Full Text] [Related]

  • 6. A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
    Sugimoto K, Suzuki HI, Fujimura T, Ono A, Kaga N, Isobe Y, Sasaki M, Taka H, Miyazono K, Komatsu N.
    Cancer Sci; 2015 Nov 08; 106(11):1534-43. PubMed ID: 26331698
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias In Vivo.
    Nguyen HA, Su Y, Zhang JY, Antanasijevic A, Caffrey M, Schalk AM, Liu L, Rondelli D, Oh A, Mahmud DL, Bosland MC, Kajdacsy-Balla A, Peirs S, Lammens T, Mondelaers V, De Moerloose B, Goossens S, Schlicht MJ, Kabirov KK, Lyubimov AV, Merrill BJ, Saunthararajah Y, Van Vlierberghe P, Lavie A.
    Cancer Res; 2018 Mar 15; 78(6):1549-1560. PubMed ID: 29343523
    [Abstract] [Full Text] [Related]

  • 9. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
    Jarrar M, Gaynon PS, Periclou AP, Fu C, Harris RE, Stram D, Altman A, Bostrom B, Breneman J, Steele D, Trigg M, Zipf T, Avramis VI.
    Pediatr Blood Cancer; 2006 Aug 15; 47(2):141-6. PubMed ID: 16425271
    [Abstract] [Full Text] [Related]

  • 10. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells.
    Aslanian AM, Kilberg MS.
    Biochem J; 2001 Aug 15; 358(Pt 1):59-67. PubMed ID: 11485552
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies.
    Ardalan N, Mirzaie S, Sepahi AA, Khavari-Nejad RA.
    Med Hypotheses; 2018 Mar 15; 112():7-17. PubMed ID: 29447943
    [Abstract] [Full Text] [Related]

  • 13. L-asparaginase anti-tumor activity in pancreatic cancer is dependent on its glutaminase activity and resistance is mediated by glutamine synthetase.
    Blachier J, Cleret A, Guerin N, Gil C, Fanjat JM, Tavernier F, Vidault L, Gallix F, Rama N, Rossignol R, Piedrahita D, Andrivon A, Châlons-Cottavoz M, Aguera K, Gay F, Horand F, Laperrousaz B.
    Exp Cell Res; 2023 May 15; 426(2):113568. PubMed ID: 36967104
    [Abstract] [Full Text] [Related]

  • 14. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI.
    Clin Cancer Res; 2004 Aug 15; 10(16):5335-41. PubMed ID: 15328169
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Targeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells.
    Nishikawa G, Kawada K, Hanada K, Maekawa H, Itatani Y, Miyoshi H, Taketo MM, Obama K.
    Cells; 2022 Oct 18; 11(20):. PubMed ID: 36291140
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
    Avramis VI, Tiwari PN.
    Int J Nanomedicine; 2006 Oct 18; 1(3):241-54. PubMed ID: 17717965
    [Abstract] [Full Text] [Related]

  • 20. Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.
    Chien WW, Le Beux C, Rachinel N, Julien M, Lacroix CE, Allas S, Sahakian P, Cornut-Thibaut A, Lionnard L, Kucharczak J, Aouacheria A, Abribat T, Salles G.
    Sci Rep; 2015 Jan 28; 5():8068. PubMed ID: 25626693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.